Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Human IL-18/IL-1F4 Protein

Click to view available options
Quantity:
10 μg
50 μg
500 μg
Description
The Recombinant Human IL-18/IL-1F4 Protein is derived from E. coli. The Recombinant Human IL-18/IL-1F4 Protein has been validated for the following applications: Bioactivity.
This product(s) resides on a Fisher Scientific GSA or VA contract. If you are viewing this page as a nonregistered user, the price(s) displayed is List Price. To view your GSA or VA contract pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. You can also view your contract price by searching for this item(s) on GSA Advantage. To place an order, contact Fisher Scientific Customer Service.
Specifications
Specifications
Accession Number | Q14116 |
For Use With (Application) | Bioactivity |
Gene ID (Entrez) | 3606 |
Molecular Weight (g/mol) | Predicted MW: 18kDa Observed MW: 18kDa, reducing conditions |
Quantity | 10 μg |
Source | E. coli-derived human IL-18/IL-1F4 protein Tyr37-Asp193 |
Storage Requirements | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. |
Endotoxin Concentration | <0.10 EU per 1μg of the protein by the LAL method. |
Gene Alias | Iboctadekin, IFN-gamma-inducing factor, IGIF, IGIFIL-1 gamma, IL18, IL-18MGC12320, IL-1F4, IL1F4iboctadekin, IL-1g, Interferon gamma-inducing factor, interleukin 18 (interferon-gamma-inducing factor), Interleukin-1 gamma, interleukin-18 |
Common Name | IL-18/IL-1F4 |
Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction